181 related articles for article (PubMed ID: 8297715)
1. Mechanism of cytotoxicity of 5,10-dideazatetrahydrofolic acid in human ovarian carcinoma cells in vitro and modulation of the drug activity by folic or folinic acid.
Erba E; Sen S; Sessa C; Vikhanskaya FL; D'Incalci M
Br J Cancer; 1994 Feb; 69(2):205-11. PubMed ID: 8297715
[TBL] [Abstract][Full Text] [Related]
2. Role of membrane folate-binding protein in the cytotoxicity of 5,10-dideazatetrahydrofolic acid in human ovarian carcinoma cell lines in vitro.
Sen S; Erba E; D'Incalci M; Bottero F; Canevari S; Tomassetti A
Br J Cancer; 1996 Feb; 73(4):525-30. PubMed ID: 8595169
[TBL] [Abstract][Full Text] [Related]
3. Cytotoxicity of antifolate inhibitors of thymidylate and purine synthesis to WiDr colonic carcinoma cells.
Smith SG; Lehman NL; Moran RG
Cancer Res; 1993 Dec; 53(23):5697-706. PubMed ID: 8242626
[TBL] [Abstract][Full Text] [Related]
4. Role of membrane-associated folate binding protein in the cytotoxicity of antifolates in KB, IGROV1, and L1210A cells.
Schultz RM; Andis SL; Shackelford KA; Gates SB; Ratnam M; Mendelsohn LG; Shih C; Grindey GB
Oncol Res; 1995; 7(2):97-102. PubMed ID: 7579732
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of 2-desamino-2-methyl-10-propagyl-5,8-dideazafolic acid cytotoxicity by 5,10-dideazatetrahydrofolate in L1210 cells with decrease in DNA fragmentation and deoxyadenosine triphosphate pools.
Kwok JB; Tattersall MH
Biochem Pharmacol; 1991 Jul; 42(3):507-13. PubMed ID: 1859463
[TBL] [Abstract][Full Text] [Related]
6. (6R)-5,10-Dideaza-5,6,7,8-tetrahydrofolic acid effects on nucleotide metabolism in CCRF-CEM human T-lymphoblast leukemia cells.
Pizzorno G; Moroson BA; Cashmore AR; Beardsley GP
Cancer Res; 1991 May; 51(9):2291-5. PubMed ID: 1707749
[TBL] [Abstract][Full Text] [Related]
7. Induction of HL-60 leukemia cell differentiation by tetrahydrofolate inhibitors of de novo purine nucleotide biosynthesis.
Sokoloski JA; Beardsley GP; Sartorelli AC
Cancer Chemother Pharmacol; 1991; 28(1):39-44. PubMed ID: 2040032
[TBL] [Abstract][Full Text] [Related]
8. Phase I study of the antipurine antifolate lometrexol (DDATHF) with folinic acid rescue.
Sessa C; de Jong J; D'Incalci M; Hatty S; Pagani O; Cavalli F
Clin Cancer Res; 1996 Jul; 2(7):1123-7. PubMed ID: 9816277
[TBL] [Abstract][Full Text] [Related]
9. Induction of HL-60 leukemia cell differentiation by the novel antifolate 5,10-dideazatetrahydrofolic acid.
Sokoloski JA; Beardsley GP; Sartorelli AC
Cancer Res; 1989 Sep; 49(17):4824-8. PubMed ID: 2758415
[TBL] [Abstract][Full Text] [Related]
10. 5,10-Dideazatetrahydrofolic acid reduces toxicity and deoxyadenosine triphosphate pool, expansion in cultured L1210 cells treated with inhibitors of thymidylate synthase.
Chong LK; Tattersall MH
Biochem Pharmacol; 1995 Mar; 49(6):819-27. PubMed ID: 7702640
[TBL] [Abstract][Full Text] [Related]
11. Multifactorial resistance to 5,10-dideazatetrahydrofolic acid in cell lines derived from human lymphoblastic leukemia CCRF-CEM.
Pizzorno G; Moroson BA; Cashmore AR; Russello O; Mayer JR; Galivan J; Bunni MA; Priest DG; Beardsley GP
Cancer Res; 1995 Feb; 55(3):566-73. PubMed ID: 7834626
[TBL] [Abstract][Full Text] [Related]
12. Quantitation of folic acid enhancement of antifolate synergism.
Gaumont Y; Kisliuk RL; Parsons JC; Greco WR
Cancer Res; 1992 Apr; 52(8):2228-35. PubMed ID: 1532766
[TBL] [Abstract][Full Text] [Related]
13. Whole-body autoradiographic disposition and plasma pharmacokinetics of 5,10-dideazatetrahydrofolic acid in mice fed folic acid-deficient or regular diets.
Pohland RC; Alati T; Lantz RJ; Grindey GB
J Pharm Sci; 1994 Oct; 83(10):1396-9. PubMed ID: 7884657
[TBL] [Abstract][Full Text] [Related]
14. Functional activity of the reduced folate carrier in KB, MA104, and IGROV-I cells expressing folate-binding protein.
Westerhof GR; Rijnboutt S; Schornagel JH; Pinedo HM; Peters GJ; Jansen G
Cancer Res; 1995 Sep; 55(17):3795-802. PubMed ID: 7641196
[TBL] [Abstract][Full Text] [Related]
15. Evidence for a relationship between intracellular GTP levels and the induction of HL-60 leukemia cell differentiation by 5,10-dideazatetrahydrofolic acid (DDATHF).
Sokoloski JA; Pizzorno G; Beardsley GP; Sartorelli AC
Oncol Res; 1993; 5(8):293-9. PubMed ID: 8012061
[TBL] [Abstract][Full Text] [Related]
16. Intracellular metabolism of 5,10-dideazatetrahydrofolic acid in human leukemia cell lines.
Pizzorno G; Sokoloski JA; Cashmore AR; Moroson BA; Cross AD; Beardsley GP
Mol Pharmacol; 1991 Jan; 39(1):85-9. PubMed ID: 1702876
[TBL] [Abstract][Full Text] [Related]
17. A new folate antimetabolite, 5,10-dideaza-5,6,7,8-tetrahydrofolate is a potent inhibitor of de novo purine synthesis.
Beardsley GP; Moroson BA; Taylor EC; Moran RG
J Biol Chem; 1989 Jan; 264(1):328-33. PubMed ID: 2909524
[TBL] [Abstract][Full Text] [Related]
18. The stereospecific cytotoxic potency of (6R) and (6S)-5,10- dideazatetrahydrofolate correlates with cellular folylpolyglutamate synthetase levels.
Lehman NL
Biochimie; 1995; 77(4):273-8. PubMed ID: 8589057
[TBL] [Abstract][Full Text] [Related]
19. Enhancement of antineoplastic activity of 5-fluorouracil in mice bearing colon 38 tumor by (6R)5,10-dideazatetrahydrofolic acid.
Pizzorno G; Davis SJ; Hartigan DJ; Russello O
Biochem Pharmacol; 1994 Jun; 47(11):1981-8. PubMed ID: 7516657
[TBL] [Abstract][Full Text] [Related]
20. Antifolates targeting purine synthesis allow entry of tumor cells into S phase regardless of p53 function.
Bronder JL; Moran RG
Cancer Res; 2002 Sep; 62(18):5236-41. PubMed ID: 12234990
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
